A 12-month Randomized, Multiple Dose, Open-label, Study Evaluating Safety, Tolerability, Pharmacokinetics/Pharmacodynamics (PK/PD) and Efficacy of an Anti-CD40 Monoclonal Antibody, CFZ533, in Combination With Mycophenolate Mofetil (MMF) and Corticosteroids (CS), With and Without Tacrolimus (Tac), in de Novo Renal Transplant Recipients
Phase of Trial: Phase I/II
Latest Information Update: 08 Aug 2017
At a glance
- Drugs CFZ 533 (Primary) ; CFZ 533 (Primary) ; Corticosteroids; Mycophenolic acid; Tacrolimus
- Indications Renal transplant rejection
- Focus Pharmacokinetics; Therapeutic Use
- Sponsors Novartis
- 10 Apr 2017 Planned End Date changed from 30 Nov 2018 to 26 Oct 2019.
- 10 Apr 2017 Planned primary completion date changed from 30 Nov 2018 to 26 Oct 2019.
- 14 Mar 2017 Planned End Date changed from 1 Nov 2018 to 30 Nov 2018.